Key result
In a 62-year-old male with metastatic dermatofibrosarcoma protuberans, treatment with imatinib resulted in a complete metabolic response on 18F-FDG PET/CT after 5 months.
Case Report (n=1)
No
18F-FDG PET/CT may be a useful surrogate marker for early response evaluation in patients with metastatic dermatofibrosarcoma protuberans treated with imatinib.
Answers are grounded in this paper and cite their sources.
May support FDG-PET/CT for early response assessment in imatinib-treated metastatic DFSP; hypothesis-generating and requires prospective validation.
Dermatofibrosarcoma protuberans (DFSP) is a rare locally aggressive tumor with distant metastases being unusual. We present a case of metastatic DFSP treated with imatinib showing complete metabolic response to treatment.
No takes yet. Share an insight, caveat, or question.
Kashyap et al. (2016) conducted a case report in Metastatic dermatofibrosarcoma protuberans (DFSP) (n=1). Imatinib was evaluated on Metabolic response on 18F-FDG PET/CT. In a 62-year-old male with metastatic dermatofibrosarcoma protuberans, treatment with imatinib resulted in a complete metabolic response on 18F-FDG PET/CT after 5 months.
Synapse has enriched 10 related papers. Consider them for comparative context: